ADC Therapeutics Income Statement (2019-2026) | ADCT

Income Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
3.76M13.15M46.50M17.29M76.32M18.99M19.28M14.49M18.05M17.41M18.46M23.03M18.84M16.43M20.85M
Cost of Revenue (Quarter)
0.12M0.50M0.53M2.27M1.29M0.59M1.32M0.37M2.51M1.22M0.85M2.06M0.84M1.20M3.47M
Gross Profit (Quarter)
3.64M12.64M45.97M15.03M75.03M18.40M17.96M14.13M15.54M16.19M17.61M20.97M18.00M15.22M17.38M
Operating items
Research & Development (Quarter)
39.53M36.80M48.95M48.54M41.68M39.48M31.34M27.08M25.73M24.30M32.50M28.93M30.09M26.80M19.88M
Selling, General & Administrative (Quarter)
19.37M16.59M19.01M18.24M19.62M15.14M12.00M9.62M12.03M10.24M10.00M9.96M8.82M8.33M9.90M
Restructuring Costs (Quarter)
13.09M0.38M
Other Operating Expenses (Quarter)
15.34M17.55M18.90M19.93M18.14M15.94M15.59M13.94M13.90M11.92M11.52M12.61M10.98M11.89M16.32M
Operating Expenses (Quarter)
74.24M70.94M86.86M86.70M79.44M70.56M58.93M50.64M51.67M46.45M54.03M51.50M62.99M47.40M46.10M
Operating Income (Quarter)
-70.48M-57.79M-40.36M-69.41M-3.11M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
EBIT (Quarter)
-70.48M-57.79M-26.00M-40.36M-69.41M-3.11M-14.90M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
Non-operating items
Non Operating Investment Income (Quarter)
2.05M-6.94M
Interest & Investment Income (Quarter)
0.01M0.02M18.31M0.02M0.27M2.30M2.37M2.70M2.95M3.25M3.44M2.05M1.93M2.47M1.99M
Other Non Operating Income (Quarter)
-1.85M-13.61M22.53M12.88M-48.20M17.47M0.04M-5.07M0.86M5.23M-2.60M2.75M1.62M-0.74M0.20M-0.18M0.93M-0.98M2.63M
Non Operating Income (Quarter)
0.69M-9.36M13.44M12.88M-37.12M-0.00M-13.00M-9.25M-12.14M-6.67M-8.05M-9.97M-11.24M-10.00M-7.72M
Net income details
EBT (Quarter)
-72.33M-71.40M-35.52M-17.83M-65.32M-51.32M-18.15M-59.69M-52.70M-45.40M-45.80M-35.71M-43.62M-38.44M-55.39M-40.97M-32.97M
Tax Provisions (Quarter)
0.24M0.14M-1.17M-0.95M-0.71M-0.26M-4.50M-0.10M0.20M0.23M0.09M0.17M1.25M
Profit After Tax (Quarter)
-72.57M-71.55M-34.38M-16.66M-64.37M-50.61M-25.48M-59.53M-48.92M-46.73M-86.95M-46.61M-36.54M-43.97M-32.06M-38.60M-56.65M-40.97M-6.41M-32.97M
Income from Continuing Operations (Quarter)
-72.57M-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Consolidated Net Income (Quarter)
-72.57M-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Income towards Parent Company (Quarter)
-72.57M-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Net Income towards Common Stockholders (Quarter)
-72.57M-71.55M-35.52M-16.66M-64.37M-50.61M-18.15M-59.43M-48.20M-45.30M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Additional items
EPS (Basic) (Quarter)
-0.95-0.93-0.46-0.22-0.84-0.65-0.23-0.74-0.59-0.55-0.56-0.38-0.42-0.36-0.50-0.30-0.21
EPS (Diluted) (Quarter)
-0.23-0.74-0.59-0.55-0.56-0.38-0.42-0.36-0.50-0.30-0.21
Shares Outstanding (Quarter)
76.73M76.74M76.75M76.82M76.91M78.37M78.15M80.81M81.47M82.26M81.71M82.55M95.69M104.82M97.16M107.20M113.74M136.45M127.07M154.14M
Shares Outstanding (Diluted) (Quarter)
78.15M80.81M81.47M82.26M81.71M82.55M95.69M104.82M97.16M107.20M113.74M136.45M127.07M154.14M
Shares Outstanding (Entity) (Quarter)
76.73M76.74M78.27M76.82M76.91M78.37M89.04M89.04M89.04M89.04M89.04M89.04M99.45M99.45M101.61M101.76M115.08M115.19M128.31M129.73M
EBITDA (Quarter)
-70.48M-57.79M-26.00M-40.36M-69.41M-3.11M-14.90M-51.57M-39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
Interest Expenses (Quarter)
2.56M4.26M9.52M9.22M8.80M11.36M3.25M10.42M10.31M12.82M-18.03M12.50M12.68M13.12M11.92M12.23M13.00M13.39M-24.15M12.35M
Tax Rate (Quarter)
-0.33%-0.20%6.56%1.45%1.39%0.44%8.54%0.22%-0.44%-0.66%-0.21%-0.43%-2.26%